Search
Piperonyl butoxide
go.drugbank.com/drugs/DB09350ApprovedVet approvedIt is used for the treatment of head, pubic (crab), and body lice. Piperonyl butoxide is a synergist. … It has no pesticidal activity of its own, but acts to increase the activity of pesticides such as carbamates, pyrethrins, pyrethroids, and rotenone.
Mixtures: Para Special Shampoo for Lice & Nits, Up and up lice killing maximum strengthCategories: Compounds used in a research, industrial, or household settingAminobenzoic acid
go.drugbank.com/drugs/DB02362ApprovedWithdrawnThe potassium salt is used therapeutically in fibrotic skin disorders.
Categories: Protectives Against UV-Radiation for Topical Use, Protectives Against UV-RadiationSomapacitan
go.drugbank.com/drugs/DB15093ApprovedInvestigational[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily.
Inositol
go.drugbank.com/drugs/DB13178ApprovedInvestigationalWithdrawn[L1113] By the FDA, inositol is considered in the list of specific substances affirmed as generally recognized as safe (GRAS).[L2561] … Myo-inositol is the cis-1,2,3,5-trans-4,6-cyclohexanehexol and it is prepared from an aqueous extract of corn kernels by precipitation and hydrolysis of crude phytate.
Mixtures: Palm Spring's PM Form Tab, For-2Sparfloxacin
go.drugbank.com/drugs/DB01208ApprovedWithdrawnSparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseVaborbactam
go.drugbank.com/drugs/DB12107ApprovedInvestigationalVabomere consists of vaborbactam and [Meropenem] for intravenous administration. … In August 2017, a combination antibacterial therapy under the market name Vabomere was approved by the FDA for the treatment of adult patients with complicated urinary tract infections (cUTI).
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseMaralixibat
go.drugbank.com/drugs/DB16226ApprovedInvestigational[L44396] On July 21, 2023, maralixibat was also approved by Health Canada.[L47541] … [L38834] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended maralixibat be granted marketing authorization for the treatment of cholestatic pruritus in patients
Ethchlorvynol
go.drugbank.com/drugs/DB00189ApprovedIllicitWithdrawnIt has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists.
Nirmatrelvir
go.drugbank.com/drugs/DB16691ApprovedInvestigational[L46921] Paxlovid was approved for use in Canada in January 2022 for the treatment of adult patients with mild-moderate COVID-19 [L39544] and later granted conditional marketing authorization by the European … [L33359] Both drugs were inhibitors of SARS-CoV-2 3CL<sup>PRO</sup>, but nirmatrelvir has the advantage of being orally bioavailable.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseMyeloblastic Leukemia
go.drugbank.com/conditions/DBCOND0042219Drugs: DaunorubicinSynonyms: Myeloid leukemia, no International Classification of Diseases for Oncology subtype